Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
Novo Nordisk(NVO) stock is priced at $47.31, giving the company a market capitalization of 210.17B. It carries a P/E multiple of 14.09 and pays a dividend yield of 2.5%.
As of 2025-12-03, Novo Nordisk(NVO) stock has fluctuated between $47.31 and $48.65. The current price stands at $47.31, placing the stock 0.0% above today's low and -2.8% off the high.
Novo Nordisk(NVO) shares are trading with a volume of 11.91M, against a daily average of 22.89M.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
NVO News
It’s the latest move in an ongoing price war between the two drugmakers that sell the incredibly lucrative medications. Eli Lilly slashed the cash-pay price fo...
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, Li...
A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?...
Analyst ratings
56%
of 32 ratingsMore NVO News
Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company. The share price of Danish pharmaceutical giant Novo Nordisk (NVO +1.3...
Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...
Wondering if Novo Nordisk is priced fairly, or if there could be a value play just waiting to be found? Let’s take a closer look at what’s been happening with t...
Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed critical information that investor...
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct the...
Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectab...
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area. Novo Nordisk (NVO +3.51%), a Denmark-based drugmaker, is currentl...
